Pharmaceutical executives spend an extra 9 hours a month learning (and teaching) online
A study run by online business networking service MeettheBoss shows that pharmaceutical executives are spending an extra 9 hours a month online sharing their professional experiences and learning from their peers. MeettheBoss surveyed 15,000 of its 200,000 executive members to understand more about what effect Web 2.0 has had on the business world.
The survey asked its executive users what direct value they gained from spending time running blogs, writing tweets and connecting with other executives on sites such as Linked-In, Xing, MeettheBoss, Ryze, Facebook and Twitter. The answers revealed that the pharmaceutical executives proficient with online activities are spending an average of 9 hours more per month online than this time last year – and over 90% of respondents said they felt their time online was ‘very valuable’ to their daily role.
Though most of these executives agree there is no substitute for face-to-face networking, using social media tools correctly can bring substantial return on your time investment.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
